Treatment with the drug candidate, acquired as part of the purchase of US biotech firm Chinook for up to $3.5 billion, resulted in a meaningful improvement in proteinuria in patients suffering from IgA nephropathy when compared to placebo, the Swiss drugmaker said in a statement.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment